Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference

被引：479

作者：

Roila, F. ^{[1
]}

Herrstedt, J. ^{[2
]}

Aapro, M. ^{[3
]}

Gralla, R. J. ^{[4
]}

Einhorn, L. H. ^{[5
]}

Ballatori, E.

Bria, E. ^{[6
]}

Clark-Snow, R. A. ^{[7
]}

Espersen, B. T. ^{[8
]}

Feyer, P. ^{[9
]}

Grunberg, S. M. ^{[10
]}

Hesketh, P. J. ^{[11
]}

Jordan, K. ^{[12
]}

Kris, M. G. ^{[13
]}

Maranzano, E. ^{[14
]}

Molassiotis, A. ^{[15
]}

Morrow, G. ^{[16
]}

Olver, I. ^{[17
]}

Rapoport, B. L. ^{[18
]}

Rittenberg, C. ^{[19
]}

Saito, M. ^{[20
]}

Tonato, M. ^{[21
]}

Warr, D. ^{[22
]}

机构：

[1] S Maria Univ Hosp, Dept Med Oncol, Terni, Italy

[2] Odense Univ Hosp, DK-5000 Odense, Denmark

[3] Inst Multidisciplinaire Oncol, Genolier, Switzerland

[4] Hofstra Univ, Sch Med, LIJ Hlth Syst, Lake Success, NY USA

[5] Walther Canc Inst, Indianapolis, IN USA

[6] Regina Elena Inst Canc Res, Rome, Italy

[7] Lawrence Mem Hosp, Lawrence, KS USA

[8] Aarhus Univ Hosp, DK-8000 Aarhus, Denmark

[9] Vivantes Clin, Clin Radiotherapy, Berlin, Germany

[10] Univ Vermont, Burlington, VT 05405 USA

[11] Lahey Clin Fdn, Burlington, MA 01805 USA

[12] Univ Halle Wittenberg, Halle, Germany

[13] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[14] S Maria Hosp, Radiat Oncol Ctr, Terni, Italy

[15] Univ Manchester, Sch Nursing, Manchester, Lancs, England

[16] Univ Rochester, Ctr Canc, Rochester, NY 14627 USA

[17] Canc Council Australia, Sydney, NSW, Australia

[18] Med Oncol Ctr Rosebank, Johannesburg, South Africa

[19] Rittenberg Oncol Consulting, Metairie, LA USA

[20] Juntendo Univ Hosp, Tokyo, Japan

[21] Umbria Reg Canc Network Perugia, Perugia, Italy

[22] Univ Toronto, Princess Margaret Hosp, Toronto, ON M5S 1A1, Canada

来源：

ANNALS OF ONCOLOGY | 2010年 / 21卷

关键词：

NEUROKININ-1 RECEPTOR ANTAGONIST; MODERATELY EMETOGENIC CHEMOTHERAPY; PLACEBO-CONTROLLED TRIAL; HIGH-DOSE CISPLATIN; DOUBLE-BLIND; PHASE-III; CASOPITANT MESYLATE; BREAST-CANCER; APREPITANT; ONDANSETRON;

D O I：

10.1093/annonc/mdq194

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：v232 / v243

页数：12

共 34 条

[1] A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy [J].

Aapro, M. S. ;

Grunberg, S. M. ;

Manikhas, G. M. ;

Olivares, G. ;

Suarez, T. ;

Tjulandin, S. A. ;

Bertoli, L. F. ;

Yunus, F. ;

Morrica, B. ;

Lordick, F. ;

Macciocchi, A. .

ANNALS OF ONCOLOGY, 2006, 17 (09) :1441-1449

[2] Phase 2 Trial Results With the Novel Neurokinin-1 Receptor Antagonist Casopitant in Combination With Ondansetron and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic Chemotherapy [J].

Arpornwirat, Wichit ;

Albert, Istvan ;

Hansen, Vincent L. ;

Levin, Jeremey ;

Bandekar, Rajesh R. ;

Grunberg, Steven M. .

CANCER, 2009, 115 (24) :5807-5816

[3]

Bria E, 2009, SUPPORT CARE CANCER, V17, P872

[4] Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting [J].

Chawla, SP ;

Grunberg, SM ;

Gralla, RJ ;

Hesketh, PJ ;

Rittenberg, C ;

Elmer, ME ;

Schmidt, C ;

Taylor, A ;

Carides, AD ;

Evans, JK ;

Horgan, KJ .

CANCER, 2003, 97 (09) :2290-2300

[5] Electroacupuncture for refractory acute emesis caused by chemotherapy [J].

Choo, Su-Pin ;

Kong, Keng-He ;

Lim, Wan-Teck ;

Gao, Fei ;

Chua, Karen ;

Leong, Swan-Swan .

JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE, 2006, 12 (10) :963-969

[6] Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy [J].

de Wit, R ;

de Boer, AC ;

von der Linden, GHM ;

Stoter, G ;

Sparreboom, A ;

Verweij, J .

BRITISH JOURNAL OF CANCER, 2001, 85 (08) :1099-1101

[7] Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist -: Results of a phase III, single-dose trial versus dolasetron [J].

Eisenberg, P ;

Figueroa-Vadillo, J ;

Zamora, R ;

Charu, V ;

Hajdenberg, J ;

Cartmell, A ;

Macciocchi, A ;

Grunberg, S .

CANCER, 2003, 98 (11) :2473-2482

[8] Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron [J].

Gralla, R ;

Lichinitser, M ;

Van der Vegt, S ;

Sleeboom, H ;

Mezger, J ;

Peschel, C ;

Tonini, G ;

Labianca, R ;

Macciocchi, A ;

Aapro, M .

ANNALS OF ONCOLOGY, 2003, 14 (10) :1570-1577

[9]

GRUNBERG SM, 2003, P AN M AM SOC CLIN, V22, pA2931

[10] Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial [J].

Grunberg, Steven M. ;

Rolski, Janusz ;

Strausz, Janos ;

Aziz, Zeba ;

Lane, Stephen ;

Russo, Mark W. ;

Wissel, Paul ;

Guckert, Mary ;

Wright, Oliver ;

Herrstedt, Jorn .

LANCET ONCOLOGY, 2009, 10 (06) :549-558

← 1 2 3 4 →